Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jul 23;373(4):307-16.
doi: 10.1056/NEJMoa1415340.

Regional Nodal Irradiation in Early-Stage Breast Cancer

Collaborators, Affiliations
Randomized Controlled Trial

Regional Nodal Irradiation in Early-Stage Breast Cancer

Timothy J Whelan et al. N Engl J Med. .

Abstract

Background: Most women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation. We examined whether the addition of regional nodal irradiation to whole-breast irradiation improved outcomes.

Methods: We randomly assigned women with node-positive or high-risk node-negative breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy to undergo either whole-breast irradiation plus regional nodal irradiation (including internal mammary, supraclavicular, and axillary lymph nodes) (nodal-irradiation group) or whole-breast irradiation alone (control group). The primary outcome was overall survival. Secondary outcomes were disease-free survival, isolated locoregional disease-free survival, and distant disease-free survival.

Results: Between March 2000 and February 2007, a total of 1832 women were assigned to the nodal-irradiation group or the control group (916 women in each group). The median follow-up was 9.5 years. At the 10-year follow-up, there was no significant between-group difference in survival, with a rate of 82.8% in the nodal-irradiation group and 81.8% in the control group (hazard ratio, 0.91; 95% confidence interval [CI], 0.72 to 1.13; P=0.38). The rates of disease-free survival were 82.0% in the nodal-irradiation group and 77.0% in the control group (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P=0.01). Patients in the nodal-irradiation group had higher rates of grade 2 or greater acute pneumonitis (1.2% vs. 0.2%, P=0.01) and lymphedema (8.4% vs. 4.5%, P=0.001).

Conclusions: Among women with node-positive or high-risk node-negative breast cancer, the addition of regional nodal irradiation to whole-breast irradiation did not improve overall survival but reduced the rate of breast-cancer recurrence. (Funded by the Canadian Cancer Society Research Institute and others; MA.20 ClinicalTrials.gov number, NCT00005957.).

PubMed Disclaimer

Figures

Figure 1
Figure 1. 10-Year Kaplan–Meier Estimates of Survival
Shown are rates of overall survival (Panel A), disease-free survival (Panel B), isolated locoregional disease-free survival (Panel C), and distant disease-free survival (Panel D) among patients who underwent whole-breast irradiation plus regional nodal irradiation (WBI + RNI) and those who underwent whole-breast irradiation alone (WBI, control group).
Figure 2
Figure 2. Disease-free Survival at 10 Years, According to Subgroup
Shown are hazard ratios and rates of disease-free survival among patients who underwent whole-breast irradiation plus regional nodal irradiation (WBI+RNI) and those who underwent whole-breast irradiation alone (WBI, control group). The dashed vertical line at 0.76 in dicates the overall hazard ratio estimate. Hazard ratios are shown on a logarithmic scale. DFS denotes disease-free survival, ER estrogen receptor, and PR progesterone receptor.

Comment in

References

    1. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665–73. - PubMed
    1. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993;328:1587–91. - PubMed
    1. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. J Natl Cancer Inst. 1996;88:1659–64. - PubMed
    1. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–62. - PubMed
    1. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–55. - PubMed

Publication types

MeSH terms

Substances

Associated data